The authors described positivity for PD-L1 (>1% of membrane-tagged tumour cells) in 33% of cases (98/298 cases) and among ICI-treated patients, PD-L1 positivity was associated with a 55.6% objective response rate (ORR), while 37.9% of PD-L1- melanoma patients had an ORR after ICI. This evidence concerns the gene CD274 and melanoma.